Interlace Gets FDA Clearance

Xconomy Boston — 

Interlace Medical, a Framingham, MA-based developer of medical devices for gynecologists, said today that the FDA has granted the firm clearance to market its MyoSure device for removing fibroids and polyps from the uterus without requiring incisions. About 80 percent of women develop uterine fibroids in their lifetime, and the annual cost of treating them in the U.S. is more than $2 billion, according to Interlace. The firm said it was gearing up to commercialize the device in June when it announced the closing a $20.5 million Series C round of financing.